Jonathan McNeill
CIK 1824673 · President and COO · last filed 2025-12-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.40M
Companies
2
Total Filings
29
Lifetime Open-Market Net
-$5.63M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | President and COO | 153,707 | $15.70 | $2.41M | $0 | 2 | 2025-12-17 |
| DYN | Chief Business Officer | 132,106 | $18.19 | $2.40M | -$5.63M | 27 | 2024-08-20 |
Recent Filings · Page 3 of 3
29 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-09-21 | DYN | Disp (D) | −1,246 | -$17.1K | EDGAR |
| 2022-09-15 | DYN | Disp (D) | −494 | -$6.9K | EDGAR |
| 2022-07-06 | DYN | Grant (A) | — | $0 | EDGAR |
| 2022-06-15 | DYN | Disp (D) | −504 | -$2.5K | EDGAR |
| 2022-03-14 | DYN | Sell (S) | −481 | -$4.2K | EDGAR |
| 2021-12-14 | DYN | Grant (A) | +25,311 | $0 | EDGAR |
| 2021-09-22 | DYN | Sell (S) | −1,274 | -$20.3K | EDGAR |
| 2021-07-13 | DYN | Grant (A) | — | $0 | EDGAR |
| 2020-09-18 | DYN | Grant (A) | +17,012 | $0 | EDGAR |
Showing 21–29 of 29
Prev
Page 3 of 3
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.